REBEC

Public trial

Comparison among two drugs commonly used in the prevention and treatment of thrombosis, to prevent thromboembolism after total cavopulmonary operation.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of a Pilates exercise program on flexibility, muscle performance and balance of elderly women.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of the effectiveness of the use of pads in adult patients admitted to the Intensive Care Unit

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of manipulation of foot muscles in people who have acquired brain injury

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Treating lymphangioleiomyomatosis with doxycycline

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The melatonin analgesic effect in a human pain model

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Oral splint and counselling for the treatment of chronic facial pain

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Cardiac responses during rehabilitation in patients undergoing cardiac surgery

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of exercise in ovseweight nondialyis dependent chronic kidney disease patients.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of methods of oral rehydration therapy in children with acute diarrhea.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of a type of therapy for the treatment of vaginal pain during intercourse.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of two types of implants installed in the jaw

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Analysis of the cardiac frequency and oxygenation during sleep in patients with the Obstructive Sleep Apnea Syndrome

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Ocular surface evaluation in ocular hypertension or inicial glaucoma patients treated with drops.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of dressing for central venous catheter

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of drug therapy in the treatment of migraine

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Homeopathic medicines as complementary treatment of cocaine dependence.

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Treatment of severe stroke guided by parameters regarding brain protection and neurological recovery

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Effects of pulmonary re-expansion maneuver on patients receiving mechanical ventilation

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of electrical stimulation and ventilatory muscle training in patients with kidney disease on hemodialysis

Date of registration: 12/20/2012 ^(mm/dd/yyyy)
Last approval date : 12/20/2012 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

04/02/2026

Data shows 6.7% of global clinical trials impacted by Middle East disruption

04/02/2026 | Abigail Beaney | Clincal Trials Arena

https://www.clinicaltrialsarena.com/news/data-shows-6-7-of-global-clinical-trials-impacted-by-middle-east-disruption/

The research found that Phase III trials are most impacted by the Middle East disruption.

An analysis of 65,061 globally recruiting clinical trials across 186 countries finds that 4,361 studies, equivalent to 6.7% of all active trials, are impacted by disruption in the Middle East.

The research, conducted by data analytics firm Phesi, found that across a total of 356,699 recruiting investigator sites, 7,958, or 2.2%, are in the affected region, with Phase III trials accounting for the highest number of impacted sites at 2,732.

The highest number of sites experiencing disruption are located in Turkey, Israel and Egypt, with oncology trials accounting for a substantial proportion of impacted activity. Additional impact is seen across conditions, including heart failure, multiple myeloma and Crohn’s disease.

The analysis also finds that large pharmaceutical companies have a substantial footprint in the region, with some organisations having between 400 and 500 sites in the Middle East.

Dr Gen Li, founder and CEO, Phesi, said: “Clinical development has become deeply interconnected. When disruption occurs, the impact extends beyond individual sites, particularly in high-priority disease areas such as oncology. The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment. Patient safety and the safety of investigators and clinical staff must remain the primary consideration, alongside the need to keep existing trials going.”

Li added that while disruption…

04/02/2026

New Guide Simplifies the Clinical Practice of Medicinal Cannabis for Prescribers in Brazil

04/01/2026 | Leandro Maia | Sechat

https://sechat.com.br/noticia/novo-guia-descomplica-a-pratica-clinica-da-cannabis-medicinal-para-prescritores-no-brasil

Wellington Briques' work brings together evidence, protocols, and trends in precision medicine to guide healthcare professionals.

With the rapid advancement of medicinal cannabis in Brazil and the increased demand for evidence-based treatments, the need for qualified training among doctors and healthcare professionals is also growing. It is in this context that the book "Simplifying the Clinical Practice of Medicinal Cannabis," by physician Wellington Briques, is scheduled for release at the end of April.

With 372 pages, the work aims to be a practical and complete guide for the clinical prescription of cannabis, covering everything from the fundamentals of the endocannabinoid system to advanced therapeutic monitoring strategies. The content is structured to offer direct support to medical practice, with clear guidance on cannabinoid selection, dose determination, titration, and patient monitoring.

The book also features a preface by physician Pedro Pierro, reinforcing the work's relevance in the context of medical education and the consolidation of cannabis as an evidence-based therapeutic tool.

The scientific basis and patient safety

In the first chapters, the book presents a robust approach to the physiology of the endocannabinoid system and its relationship with the main cannabinoids used in clinical practice. The aim is to build a solid foundation for safer and more assertive therapeutic decisions.

One of the book's distinguishing features is its emphasis on safety: contraindications, possible drug interactions, and clinical criteria are detailed with a focus…

04/02/2026

Brazilian National Cancer Institute (INCA) Announces Study on Lung Cancer Screening in the Brazilian Public Health System (SUS)

04/01/2026 | Lígia Formenti | Jota

https://www.jota.info/saude/inca-anuncia-estudo-sobre-rastreamento-de-cancer-de-pulmao-no-sus

The results will be used to identify the possibility of developing a national guideline for detecting the disease.

The National Cancer Institute (INCA) will conduct a groundbreaking study to implement a lung cancer screening program in the Unified Health System (SUS). The results will be used to identify the possibility of developing a national guideline for detecting the disease, the leading cause of cancer death in Brazil.

INCA estimates indicate that the country will have approximately 35,380 new cases of lung cancer per year in the period 2026–2028, with approximately 18,730 cases in men and 16,650 in women.

The death toll is also significant. The high mortality rate is associated with late diagnosis. The general director of INCA (National Cancer Institute), Roberto Gil, notes that 85% of cases are identified at an advanced stage. “At INCA, 50% of patients do not begin treatment because they have already missed the window of opportunity,” observed the director during the research launch ceremony in Rio.

Funded by AstraZeneca and conducted in partnership with the Rio Municipal Health Department, the study is expected to last two years. During this period, 397 people will be monitored. Volunteers will be recruited from the Smoking Cessation Program of the Rio Municipal Health Department.

The choice is not accidental. Approximately 85% of lung cancer cases are associated with the consumption of tobacco products. To participate in the study, volunteers must fit a specific profile: be between 50 and 80 years old, smokers or former smokers who have quit smoking in the last 15 years, without a cancer diagnosis or symptoms related to the disease,…

04/02/2026

Opinion: New Legal Framework for Clinical Research Could Inject Billions into Brazil

04/01/2026 | Fábio Franke | Exame

https://exame.com/bussola/novo-marco-legal-da-pesquisa-clinica-pode-injetar-bilhoes-no-brasil/?utm_source=copiaecola&utm_medium=compartilhamento

Understand how the new regulation corrects historical distortions and positions the country as a strategic hub for global protocols.

The vaccine that prevented millions of deaths in the pandemic. The most modern cancer treatments that increased survival rates in cases previously considered incurable.

And even advances in regenerative therapies with the use of polyamine in spinal cord injuries that challenge limits previously considered impossible. None of this would be possible without clinical research.

The urgency of access and the time factor

For those facing a complex diagnosis, especially an oncological one, the clock doesn't run in years, it runs in decisions. In access. In opportunity. Before reaching the doctor's office, every advance that today seems "normal" had to begin as a hypothesis, go through years of testing, and, above all, gain time. Time for study, approval, and access.

It is under this urgency that Law No. 14,874/2024, the new legal framework for clinical research in Brazil, should be understood.

Economic Impact and New Investments

The approval of the law represents more than a regulatory advance. It corrects a historical distortion: the slowness that isolated Brazilian science from the rest of the world.

Today, the country accounts for less than 2% of global clinical research, a clear mismatch between capacity and participation. The expectation is that Brazil will attract approximately R$ 3 billion annually in direct investments and up to R$ 5 billion…

04/01/2026

The Indo-Australian Biotech Bridge: Strategic Synergies in Clinical Trials

04/01/2026 | The Policy Edge

https://www.policyedge.in/p/the-indo-australian-biotech-bridge-strategic-synergies-in-clinical-trials

The Australian Trade and Investment Commission (Austrade) has highlighted a burgeoning strategic partnership at BioAsia 2026, driven by India’s AUD 236 billion biotech sector seeking Australia’s regulatory speed.

Indian innovators are increasingly utilising Australia’s Clinical Trial Notification (CTN) pathway, which allows trials to commence immediately after ethics approval, often within 6 to 12 weeks, compared to traditional 16-week timelines elsewhere. This "Fast-Track" access is coupled with a high degree of Data Governance; Australian Phase 1 data is widely accepted by the US FDA and European EMA.

While Australia provides rapid, high-quality early-phase data and significant R&D tax benefits, India offers the late-phase scale, massive patient populations, and cost-effective manufacturing necessary for global commercialisation.

Strategic Components of the Biotech Corridor

Regulatory Efficiency: Australia’s risk-based CTN system offers a competitive advantage for firms racing for "first-in-human" or "proof-of-concept" data.
Global Market Entry: Australian trial results act as a validated gateway for Indian firms targeting high-value markets in Boston, Paris, and beyond.
Complementary Strengths: The partnership creates a "Practical Pathway" where Australia handles early-phase precision and India manages development volume and mass production.
Manufacturing Synergy: Australian biotech firms are simultaneously looking to India to leverage its immense manufacturing capacity to bring Australian discoveries to the global market.